SG10201811729PA - Membrane-penetrating peptides to enhance transfection and compositions and methods for using same - Google Patents
Membrane-penetrating peptides to enhance transfection and compositions and methods for using sameInfo
- Publication number
- SG10201811729PA SG10201811729PA SG10201811729PA SG10201811729PA SG10201811729PA SG 10201811729P A SG10201811729P A SG 10201811729PA SG 10201811729P A SG10201811729P A SG 10201811729PA SG 10201811729P A SG10201811729P A SG 10201811729PA SG 10201811729P A SG10201811729P A SG 10201811729PA
- Authority
- SG
- Singapore
- Prior art keywords
- cargo
- membrane
- compositions
- methods
- peptides
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 8
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 7
- 238000001890 transfection Methods 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- -1 cationic lipid Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
- A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361915429P | 2013-12-12 | 2013-12-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201811729PA true SG10201811729PA (en) | 2019-02-27 |
Family
ID=52273587
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201811729PA SG10201811729PA (en) | 2013-12-12 | 2014-12-12 | Membrane-penetrating peptides to enhance transfection and compositions and methods for using same |
| SG11201604697TA SG11201604697TA (en) | 2013-12-12 | 2014-12-12 | Membrane-penetrating peptides to enhance transfection and compositions and methods for using same |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201604697TA SG11201604697TA (en) | 2013-12-12 | 2014-12-12 | Membrane-penetrating peptides to enhance transfection and compositions and methods for using same |
Country Status (11)
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10066000B2 (en) | 2012-05-02 | 2018-09-04 | Life Technologies Corporation | High yield transient expression in mammalian cells using unique pairing of high density growth and transfection medium and expression enhancers |
| CN104823168B (zh) | 2012-06-15 | 2018-11-09 | 英特尔公司 | 用于实现从由加载存储重新排序和优化导致的推测性转发遗漏预测/错误中恢复的方法和系统 |
| KR101818967B1 (ko) | 2012-06-15 | 2018-01-16 | 인텔 코포레이션 | 명확화 없는 비순차 load store 큐 |
| EP2862069A4 (en) | 2012-06-15 | 2016-12-28 | Soft Machines Inc | INSTRUCTION DEFINITION FOR IMPLEMENTING LOAD MEMORY TRANSFER AND OPTIMIZATION |
| CN107748673B (zh) | 2012-06-15 | 2022-03-25 | 英特尔公司 | 包括虚拟加载存储队列的处理器和系统 |
| EP2862062B1 (en) | 2012-06-15 | 2024-03-06 | Intel Corporation | A virtual load store queue having a dynamic dispatch window with a distributed structure |
| KR101996592B1 (ko) | 2012-06-15 | 2019-07-04 | 인텔 코포레이션 | 명확화 없는 비순차 load store 큐를 갖는 재정렬된 투기적 명령어 시퀀스들 |
| CN113105559A (zh) | 2013-12-12 | 2021-07-13 | 生命技术公司 | 增强转染的膜穿透性肽和组合物以及其使用方法 |
| CA2976376A1 (en) | 2015-02-13 | 2016-08-18 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
| JP6865207B2 (ja) | 2015-07-13 | 2021-04-28 | ライフ テクノロジーズ コーポレーション | Ｃｈｏ細胞における改善された一過性タンパク質発現のための系及び方法 |
| WO2017151733A1 (en) * | 2016-03-01 | 2017-09-08 | Molecular Transfer, Inc. | Plant virus movement proteins and methods of using the same |
| IL264439B2 (en) | 2016-08-17 | 2024-08-01 | Factor Bioscience Inc | A suitable viral preparation containing a synthetic messenger RNA encoding a gene editing protein for use in cancer treatment and a synthetic messenger RNA encoding a gene editing protein for use in therapy |
| CN109890959A (zh) | 2016-09-30 | 2019-06-14 | 生命技术公司 | 慢病毒生产用的无血清悬浮液系统 |
| US11782050B2 (en) | 2017-09-19 | 2023-10-10 | Cannametrix, Llc | Cell-based assay for quantifying the potency and efficacy of cannabinoids and/or terpenoids, and methods of use thereof |
| JP7596148B2 (ja) * | 2018-03-16 | 2024-12-09 | サレプタ セラピューティクス， インコーポレイテッド | アンチセンス送達用キメラペプチド |
| WO2020077178A1 (en) * | 2018-10-12 | 2020-04-16 | Ann & Robert H. Lurie Children's Hospital of Chicago | Plga-peg/pei nanoparticles and methods of use |
| GB201821269D0 (en) | 2018-12-28 | 2019-02-13 | Nippon Shinyaku Co Ltd | Myostatin signal inhibitor |
| JP2022521755A (ja) * | 2019-02-22 | 2022-04-12 | ライフ テクノロジーズ コーポレーション | アデノ随伴ウイルスの産生のための浮遊システム |
| KR102261371B1 (ko) * | 2019-04-01 | 2021-06-08 | 한양대학교 산학협력단 | CP2c 표적 펩티드 기반 항암제 |
| CN113874029B (zh) * | 2019-04-01 | 2025-02-11 | 汉阳大学校产学协力团 | 基于cp2c靶向肽的抗癌剂 |
| CN117551696A (zh) * | 2019-08-05 | 2024-02-13 | 宝利普拉斯生物转染公司 | 包含接枝到阳离子聚合物上的三唑化合物的用于将核酸分子转染到细胞中的组合物及其应用 |
| KR102515464B1 (ko) * | 2020-04-29 | 2023-03-28 | 연세대학교 원주산학협력단 | 핵산 또는 유전자 형질감염 효율을 개선하는 세포독성 완화 막 투과 펩타이드 및 이의 용도 |
| WO2022165608A1 (en) * | 2021-02-08 | 2022-08-11 | University Of British Columbia | Anti-synucleinopathy peptide and methods to treat neurodegenrative diseases |
| EP4368176A4 (en) | 2021-07-08 | 2025-06-25 | Nippon Shinyaku Co., Ltd. | Nephrotoxicity reducing agent |
| AU2022306820A1 (en) | 2021-07-08 | 2024-01-04 | Nippon Shinyaku Co., Ltd. | Nephrotoxicity reducing agent |
| EP4368187A4 (en) | 2021-07-08 | 2025-07-02 | Nippon Shinyaku Co Ltd | PRECIPITATION INHIBITING AGENT |
| CN113563429A (zh) * | 2021-07-19 | 2021-10-29 | 天津大学 | 一种基于烷基化多肽的核酸递送系统及制备方法与应用 |
| US20240336655A1 (en) * | 2021-08-04 | 2024-10-10 | AJK Biopharmaceutical, LLC | Amphiphilic peptides for nucleic acid and protein delivery |
| CN114106095B (zh) * | 2021-11-11 | 2023-06-09 | 华南理工大学 | 基于聚集诱导发光原理的细胞自噬检测分子探针及其制备方法和应用 |
| JPWO2023171804A1 (enrdf_load_stackoverflow) | 2022-03-10 | 2023-09-14 | ||
| KR102717793B1 (ko) * | 2022-05-26 | 2024-10-16 | 주식회사 바이오셀트란 | 신규한 미백 펩타이드 및 이를 함유하는 화장료 조성물 |
| WO2024006937A1 (en) | 2022-06-30 | 2024-01-04 | Life Technologies Corporation | Lipid compositions for in vivo delivery |
| GB202211597D0 (en) | 2022-08-09 | 2022-09-21 | Nchain Licensing Ag | Computer-implemented method and system |
| CN120615011A (zh) | 2022-12-29 | 2025-09-09 | 生命科技股份有限公司 | 脂质组合物及用于递送到免疫细胞的方法 |
| CN115947817B (zh) * | 2023-02-22 | 2024-07-02 | 甘肃中肽生物科技有限公司 | 一种肿瘤相关多肽及其制备方法和应用 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| FR2645866B1 (fr) | 1989-04-17 | 1991-07-05 | Centre Nat Rech Scient | Nouvelles lipopolyamines, leur preparation et leur emploi |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| US5334761A (en) | 1992-08-28 | 1994-08-02 | Life Technologies, Inc. | Cationic lipids |
| US5316948A (en) | 1992-09-04 | 1994-05-31 | Life Technologies, Inc. | N4 -methyl-2'-deoxycytidine 5'-triphosphate and its use in polymerase-catalyzed nucleic acid syntheses |
| WO1995002698A1 (en) | 1993-07-12 | 1995-01-26 | Life Technologies, Inc. | Composition and methods for transfecting eukaryotic cells |
| US5674908A (en) | 1993-12-20 | 1997-10-07 | Life Technologies, Inc. | Highly packed polycationic ammonium, sulfonium and phosphonium lipids |
| US6075012A (en) | 1994-02-11 | 2000-06-13 | Life Technologies, Inc. | Reagents for intracellular delivery of macromolecules |
| US5627159A (en) | 1994-10-27 | 1997-05-06 | Life Technologies, Inc. | Enhancement of lipid cationic transfections in the presence of serum |
| US6051429A (en) * | 1995-06-07 | 2000-04-18 | Life Technologies, Inc. | Peptide-enhanced cationic lipid transfections |
| WO1996040961A1 (en) | 1995-06-07 | 1996-12-19 | Life Technologies, Inc. | Peptide-enhanced cationic lipid transfections |
| US5744335A (en) | 1995-09-19 | 1998-04-28 | Mirus Corporation | Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein |
| SE9804614A0 (en) | 1998-07-06 | 2000-01-07 | A+ Science Invest Ab | New peptides and use thereof |
| CA2350882C (en) | 1998-11-12 | 2011-02-22 | Invitrogen Corporation | Transfection reagents |
| US6664040B2 (en) | 2000-05-23 | 2003-12-16 | The Regents Of The University Of California | Compositions and methods for delivery of a molecule into a cell |
| AU8466501A (en) | 2000-07-21 | 2002-02-05 | Essentia Biosystems Inc | Multi-component biological transport systems |
| GB0103110D0 (en) | 2000-08-25 | 2001-03-28 | Aventis Pharma Inc | A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1 |
| GB0106315D0 (en) * | 2001-03-14 | 2001-05-02 | Ich Productions Ltd | Transfection complexes |
| CA2513072A1 (en) | 2003-01-09 | 2004-07-29 | Invitrogen Corporation | Cellular delivery and activation polypeptide-nucleic acid complexes |
| EP1628647A4 (en) | 2003-05-22 | 2007-10-24 | Molecular Transfer Inc | LIPIDS FOR THE TRANSFECTION OF NUCLEIC ACIDS |
| ES2330115T3 (es) * | 2003-08-14 | 2009-12-04 | Cellectis | Composicion antibacteriana, mas particilarmente contra las bacterias gram-negativas, que comprende un peptido y un agente antibacteriano ventajosamente hidrofobo. |
| US20050288246A1 (en) * | 2004-05-24 | 2005-12-29 | Iversen Patrick L | Peptide conjugated, inosine-substituted antisense oligomer compound and method |
| AU2006325030B2 (en) * | 2005-12-16 | 2012-07-26 | Cellectis | Cell penetrating peptide conjugates for delivering nucleic acids into cells |
| ES2361621T7 (es) | 2005-12-30 | 2012-06-14 | Evonik Rohm Gmbh | Peptidos de lactoferrina utiles como peptidos de penetracion celular. |
| US8410045B2 (en) | 2006-03-30 | 2013-04-02 | Drais Pharmaceuticals, Inc. | Camptothecin-peptide conjugates and pharmaceutical compositions containing the same |
| AU2006343357A1 (en) | 2006-05-05 | 2007-11-15 | Molecular Transfer, Inc. | Novel reagents for transfection of eukaryotic cells |
| WO2008108505A1 (ja) | 2007-03-07 | 2008-09-12 | Japan As Represented By President Of International Medical Center Of Japan | 新規核内移行ペプチド |
| EP2379577A4 (en) | 2008-12-23 | 2012-08-29 | Vivoscript Inc | COMPOSITIONS AND METHODS FOR CELL REPROGRAMMING WITHOUT GENETIC MODIFICATION |
| US20110053829A1 (en) * | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
| WO2011127210A1 (en) | 2010-04-06 | 2011-10-13 | Massachusetts Institute Of Technology | Targeted delivery of nucleic acids |
| US9132198B2 (en) | 2010-05-30 | 2015-09-15 | The Governing Council Of The University Of Toronto | Mitochondrial penetrating peptides as carriers for anticancer compounds |
| EP2579899B1 (en) | 2010-06-14 | 2017-03-15 | F. Hoffmann-La Roche AG | Cell-penetrating peptides and uses thereof |
| US9006417B2 (en) | 2010-06-30 | 2015-04-14 | Protiva Biotherapeutics, Inc. | Non-liposomal systems for nucleic acid delivery |
| JP2014508102A (ja) | 2010-11-15 | 2014-04-03 | ライフ テクノロジーズ コーポレーション | アミン含有トランスフェクション試薬ならびにそれを生成および使用するための方法 |
| CN102153629B (zh) * | 2011-01-20 | 2013-07-24 | 华中科技大学 | 一种短肽及其应用 |
| US8853145B2 (en) * | 2011-11-14 | 2014-10-07 | Carlos Witte-Hoffmann | BLID; a novel protein domain for interaction with the Bcl-2 family of proteins |
| AU2013231851A1 (en) | 2012-03-15 | 2014-09-11 | Permeon Biologics, Inc. | Cell penetrating compositions for delivery of intracellular antibodies and antibody-like moieties and methods of use |
| CN113105559A (zh) | 2013-12-12 | 2021-07-13 | 生命技术公司 | 增强转染的膜穿透性肽和组合物以及其使用方法 |
| KR102476764B1 (ko) * | 2015-12-23 | 2022-12-14 | 에스케이하이닉스 주식회사 | 소자분리구조 및 그 제조 방법 |
| US9926825B2 (en) | 2016-04-19 | 2018-03-27 | GM Global Technology Operations LLC | Method and apparatus for exhaust purification for an internal combustion engine |
-
2014
- 2014-12-12 CN CN202110386654.2A patent/CN113105559A/zh active Pending
- 2014-12-12 SG SG10201811729PA patent/SG10201811729PA/en unknown
- 2014-12-12 AU AU2014361806A patent/AU2014361806B2/en active Active
- 2014-12-12 US US14/569,583 patent/US9856496B2/en active Active
- 2014-12-12 EP EP20176262.2A patent/EP3756690A3/en active Pending
- 2014-12-12 BR BR112016013516A patent/BR112016013516A8/pt not_active Application Discontinuation
- 2014-12-12 SG SG11201604697TA patent/SG11201604697TA/en unknown
- 2014-12-12 JP JP2016538724A patent/JP6912887B2/ja active Active
- 2014-12-12 KR KR1020167018604A patent/KR102532559B1/ko active Active
- 2014-12-12 WO PCT/US2014/070176 patent/WO2015089487A1/en not_active Ceased
- 2014-12-12 CA CA2933561A patent/CA2933561A1/en active Pending
- 2014-12-12 EP EP14821440.6A patent/EP3079723B1/en active Active
- 2014-12-12 CN CN201480074785.5A patent/CN106456793B/zh active Active
- 2014-12-12 ES ES14821440T patent/ES2808866T3/es active Active
-
2017
- 2017-11-13 US US15/811,423 patent/US10760098B2/en active Active
-
2019
- 2019-09-17 JP JP2019168228A patent/JP6985347B2/ja active Active
-
2020
- 2020-03-19 AU AU2020202002A patent/AU2020202002B2/en active Active
- 2020-08-28 US US17/006,629 patent/US12152248B2/en active Active
-
2024
- 2024-10-10 US US18/911,619 patent/US20250109412A1/en active Pending
-
2025
- 2025-01-17 US US19/030,391 patent/US20250263751A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP6985347B2 (ja) | 2021-12-22 |
| KR20160103024A (ko) | 2016-08-31 |
| AU2020202002B2 (en) | 2021-08-05 |
| ES2808866T3 (es) | 2021-03-02 |
| CN106456793A (zh) | 2017-02-22 |
| AU2014361806B2 (en) | 2019-12-19 |
| US20250109412A1 (en) | 2025-04-03 |
| KR102532559B1 (ko) | 2023-05-16 |
| US20200392537A1 (en) | 2020-12-17 |
| CN106456793B (zh) | 2021-04-30 |
| US12152248B2 (en) | 2024-11-26 |
| EP3756690A2 (en) | 2020-12-30 |
| US20180163231A1 (en) | 2018-06-14 |
| US20150211021A1 (en) | 2015-07-30 |
| AU2020202002A1 (en) | 2020-04-09 |
| JP6912887B2 (ja) | 2021-08-04 |
| SG11201604697TA (en) | 2016-07-28 |
| JP2020015747A (ja) | 2020-01-30 |
| US20250263751A1 (en) | 2025-08-21 |
| BR112016013516A8 (pt) | 2020-05-19 |
| CA2933561A1 (en) | 2015-06-18 |
| WO2015089487A1 (en) | 2015-06-18 |
| US10760098B2 (en) | 2020-09-01 |
| EP3079723B1 (en) | 2020-05-27 |
| US9856496B2 (en) | 2018-01-02 |
| CN113105559A (zh) | 2021-07-13 |
| AU2014361806A1 (en) | 2016-07-28 |
| JP2017500856A (ja) | 2017-01-12 |
| BR112016013516A2 (enrdf_load_stackoverflow) | 2017-08-08 |
| EP3756690A3 (en) | 2021-03-17 |
| EP3079723A1 (en) | 2016-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201811729PA (en) | Membrane-penetrating peptides to enhance transfection and compositions and methods for using same | |
| Zuris et al. | Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo | |
| EP4249036A3 (en) | Methods and products for nucleic acid production and delivery | |
| WO2010129023A3 (en) | Supercharged proteins for cell penetration | |
| WO2008147816A3 (en) | Compositions and methods for the display of proteins on the surface of bacteria and their derived vesicles and uses thereof | |
| BR112013024220B8 (pt) | Métodos de introdução de um ácido nucleico de interesse em uma célula vegetal com parede celular, de expressão estável de um gene e de transferência de um gene para uma célula vegetal | |
| EP4406585A3 (en) | Nucleic acid products and methods of administration thereof | |
| EA201790968A1 (ru) | Опосредуемая пептидом доставка направляемой рнк эндонуклеазы в клетки | |
| BRPI0816405B8 (pt) | complexos de rna e pepitídeos catiônicos para transfecção e para imunoestimulação | |
| MX2009013325A (es) | Transfeccion y transduccion de plantas con base en nano acarreadores. | |
| EA201792044A1 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака | |
| EP4434997A3 (en) | Delivery of negatively charged proteins using cationic lipids | |
| WO2010115052A3 (en) | Induced pluripotent stem cells | |
| WO2007130073A3 (en) | Novel reagents for transfection of eukaryotic cells | |
| EP2583976A3 (en) | Peptide vaccines with SEQ ID NO: 210, 196, 202, 213, 214, 214 or 223 for cancers expressing tumor-associated antigens | |
| WO2012135805A3 (en) | Delivery and formulation of engineered nucleic acids | |
| BRPI0620806B8 (pt) | complexo e composição compreendendo um peptídeo e uma molécula carga, e uso da referida composição | |
| AU2012300633A8 (en) | Cell- penetrating peptides having a central hydrophobic domain | |
| MX2015016588A (es) | Estructura, fabricacion y usos de los peptidos permeables a las celulas, derivados de humanos, conjugados con los peptidos de carga especificos, biologicamente activos. | |
| RU2014110901A (ru) | Пептидные частицы и их применение | |
| MX2010005451A (es) | Sistema para la liberacion en una celula positiva para xcr1 y usos de este. | |
| WO2023018990A3 (en) | Lipids for nucleic acid delivery | |
| AU2012358181A8 (en) | Compositions and methods for the delivery of biologically active RNAs | |
| RU2013116447A (ru) | Системы и способы доставки биоактивных средств с применением транспортных последовательностей, происходящих от бактериального токсина | |
| IN2014DN09963A (enrdf_load_stackoverflow) |